Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Book

Dupilumab

Anita Gade  1 , Hira Ghani  2 , Preeti Patel, Richard Rubenstein  3
In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan.
.
Affiliations
Free Books & Documents
Book

Dupilumab

Anita Gade et al.
Free Books & Documents

Excerpt

Dupilumab is an injectable prescription medication administered subcutaneously to treat severe and refractory forms of atopic dermatitis. The US Food and Drug Administration (FDA) approved the medication in April 2017 to treat moderate-to-severe, resistant, atopic dermatitis unresponsive to conventional therapy, including topical corticosteroids. Dupilumab is also used as a maintenance treatment for asthma and chronic rhinosinusitis with nasal polyposis in adults and children, in conjunction with other medications.

PubMed Disclaimer

Conflict of interest statement

Disclosure: Anita Gade declares no relevant financial relationships with ineligible companies.

Disclosure: Hira Ghani declares no relevant financial relationships with ineligible companies.

Disclosure: Preeti Patel declares no relevant financial relationships with ineligible companies.

Disclosure: Richard Rubenstein declares no relevant financial relationships with ineligible companies.

References

    1. Maloney NJ, Tegtmeyer K, Zhao J, Worswick S. Dupilumab in Dermatology: Potential for Uses Beyond Atopic Dermatitis. J Drugs Dermatol. 2019 Oct 01;18(10) - PubMed
    1. Vangipuram R, Tyring SK. Dupilumab for Moderate-to-Severe Atopic Dermatitis. Skin Therapy Lett. 2017 Nov;22(6):1-4. - PubMed
    1. Napolitano M, Di Guida A, Nocerino M, Fabbrocini G, Patruno C. The emerging role of dupilumab in dermatological indications. Expert Opin Biol Ther. 2021 Nov;21(11):1461-1471. - PubMed
    1. Seegräber M, Srour J, Walter A, Knop M, Wollenberg A. Dupilumab for treatment of atopic dermatitis. Expert Rev Clin Pharmacol. 2018 May;11(5):467-474. - PubMed
    1. Senner S, Seegräber M, Frey S, Kendziora B, Eicher L, Wollenberg A. Dupilumab for the treatment of adolescents with atopic dermatitis. Expert Rev Clin Immunol. 2020 Jul;16(7):641-650. - PubMed

Publication types

LinkOut - more resources